Hexarelin

Overview

Hexarelin is one of the most potent growth hormone-releasing peptides (GHRPs) ever synthesized — and it does something no other GHRP does: it has a second, completely separate mechanism that protects the heart directly, independent of growth hormone entirely.

It's a synthetic six-amino acid peptide developed in the 1990s that mimics ghrelin's ability to stimulate GH secretion from the pituitary.[1] What researchers didn't expect was that hexarelin also binds the CD36 receptor in cardiac tissue, a pathway that appears to mediate meaningful cardioprotective effects in ischemia models.[2] That dual-receptor profile — GHSR plus CD36 — is what makes hexarelin genuinely interesting beyond the rest of the GHRP class.

It has no FDA approval, no compounding pathway, and sits firmly in research-compound territory. If you're reading this to understand what the science says, you're in the right place.

Mechanism of Action

GHSR agonism (GH release) + CD36 receptor binding (cardioprotection)

Hexarelin's primary job is to mimic ghrelin — the "hunger hormone" that also happens to be a powerful GH secretagogue. When hexarelin binds GHSR in the pituitary gland and hypothalamus, it triggers the pituitary to release a pulse of growth hormone into circulation.[1] That GH pulse then drives downstream effects: IGF-1 production in the liver, protein synthesis in muscle, lipolysis in fat tissue.

What makes hexarelin chemically interesting is that it's more stable than ghrelin itself.[2] Ghrelin is an endogenous 28-amino acid peptide that degrades quickly; hexarelin's 6-amino acid structure is more resistant to enzymatic breakdown, which is part of why researchers have found it useful as a pharmacological tool.

The CD36 story is separate and worth understanding on its own terms. CD36 is expressed heavily in the heart and blood vessels — tissues where you wouldn't necessarily expect a GH-releasing peptide to have much to do. When hexarelin binds CD36 in cardiac cells, it appears to activate anti-apoptotic pathways that reduce the cell death cascade triggered by ischemia and reperfusion injury.[2] This isn't a GH-mediated effect. It's a direct receptor interaction in the heart that would happen even in a GH-deficient or GH-normal patient.

The MDM2/p53 pathway finding in kidney injury adds a third layer.[5] MDM2 is a negative regulator of p53 — the protein that, when activated, drives cells toward apoptosis. Hexarelin appears to upregulate MDM2, which suppresses p53 activity and reduces programmed cell death in ischemic kidney tissue. Whether this translates to clinical benefit in humans remains an open question.

What the Evidence Shows

The honest summary: the human evidence for hexarelin is early-stage and primarily focused on GH secretion dynamics, not clinical outcomes. The cardioprotective and organ-protective findings are largely from animal models.

The foundational human pharmacology work comes from a 1996 study in Clinical Endocrinology that characterized the GH response to repeated hexarelin administration.[3] The study administered two intravenous boluses of hexarelin, GHRH (growth hormone releasing hormone), or a combination, and tracked pituitary responsiveness over time. The key finding: repeated hexarelin dosing produces desensitization — the GH response diminishes with continuous administration. Crucially, the pituitary retained its responsiveness to GHRH even after hexarelin-induced desensitization, which suggests the blunting occurs at or above the level of GHSR rather than at the pituitary itself.[3] That distinction matters practically: cycling off hexarelin while maintaining GHRH sensitivity means recovery of the GH axis is possible.

A 2008 review in the Journal of Endocrinological Investigation characterized hexarelin as a "multi-receptor peptide" — acknowledging that the GHSR and CD36 pathways give it a pharmacological profile that doesn't fit cleanly into the standard GHRP framework.[6]

The cardiovascular evidence was synthesized in a 2014 review in the Journal of Geriatric Cardiology, which documented hexarelin's peripheral distribution in heart and blood vessels and its CD36-mediated cardioprotective effects.[2] This review noted that hexarelin is chemically more stable and functionally more specific than ghrelin in some cardiac contexts — a meaningful distinction when thinking about therapeutic applications.

The 2023 kidney injury paper used an ischemia/reperfusion model to demonstrate that hexarelin reduced apoptosis via MDM2/p53 signaling.[5] This is animal data, and the authors explicitly noted that the mechanism in human AKI remains unclear.

Side Effects
Hexarelin's side effect profile follows the general GHRP pattern, with a few specific concerns tied to its higher potency and the desensitization issue.

If you experience persistent joint pain, significant edema, or symptoms of elevated intracranial pressure (headache, visual changes), stop use and consult a physician — these are known class-level concerns with sustained GH elevation.